ArticleEMBO molecular medicine2026
Human prostaglandin reductases dearomatize and inactivate benzothiazinone antitubercular drugs.
Abstract read
In one paragraph
Article in EMBO molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
37 authors.
Myriam BrikiLaboratory & Service of Medical Pharmacology, Department of Laboratory Medicine and Pathology, and Department of Medicine, University Hospital of Lausanne and University of Lausanne, Lausanne, Switzerland.
Caroline A WagnerLaboratory & Service of Medical Pharmacology, Department of Laboratory Medicine and Pathology, and Department of Medicine, University Hospital of Lausanne and University of Lausanne, Lausanne, Switzerland.ORCID http://orcid.org/0009-0009-1709-5468
Vincent DesfontaineLaboratory & Service of Medical Pharmacology, Department of Laboratory Medicine and Pathology, and Department of Medicine, University Hospital of Lausanne and University of Lausanne, Lausanne, Switzerland.
Anthony VocatInstitute of Microbiology, Department of Laboratory Medicine and Pathology, University Hospital of Lausanne and University of Lausanne, Lausanne, Switzerland.
Onya OpotaInstitute of Microbiology, Department of Laboratory Medicine and Pathology, University Hospital of Lausanne and University of Lausanne, Lausanne, Switzerland.
Sarah Abou-ZiteLaboratory & Service of Medical Pharmacology, Department of Laboratory Medicine and Pathology, and Department of Medicine, University Hospital of Lausanne and University of Lausanne, Lausanne, Switzerland.
Océane CorpatauxLaboratory & Service of Medical Pharmacology, Department of Laboratory Medicine and Pathology, and Department of Medicine, University Hospital of Lausanne and University of Lausanne, Lausanne, Switzerland.
Benedetta CenaLaboratory & Service of Medical Pharmacology, Department of Laboratory Medicine and Pathology, and Department of Medicine, University Hospital of Lausanne and University of Lausanne, Lausanne, Switzerland.
Sylvie GuinchardLaboratory & Service of Medical Pharmacology, Department of Laboratory Medicine and Pathology, and Department of Medicine, University Hospital of Lausanne and University of Lausanne, Lausanne, Switzerland.
François VersaceLaboratory & Service of Medical Pharmacology, Department of Laboratory Medicine and Pathology, and Department of Medicine, University Hospital of Lausanne and University of Lausanne, Lausanne, Switzerland.
Amarande MurisierLaboratory & Service of Medical Pharmacology, Department of Laboratory Medicine and Pathology, and Department of Medicine, University Hospital of Lausanne and University of Lausanne, Lausanne, Switzerland.
Thomas MercierLaboratory & Service of Medical Pharmacology, Department of Laboratory Medicine and Pathology, and Department of Medicine, University Hospital of Lausanne and University of Lausanne, Lausanne, Switzerland.ORCID http://orcid.org/0000-0003-1921-4837
Emilyne BlattesInnovative Medicines for Tuberculosis (iM4TB), Lausanne, Switzerland.
Carine BardinetLaboratory & Service of Medical Pharmacology, Department of Laboratory Medicine and Pathology, and Department of Medicine, University Hospital of Lausanne and University of Lausanne, Lausanne, Switzerland.
Paul ThoueilleLaboratory & Service of Medical Pharmacology, Department of Laboratory Medicine and Pathology, and Department of Medicine, University Hospital of Lausanne and University of Lausanne, Lausanne, Switzerland.
Vladimir WsolFaculty of Pharmacy in Hradec Králové, Charles University, Prague, Czech Republic.ORCID http://orcid.org/0000-0003-3745-7648
Lenka LastovickovaFaculty of Pharmacy in Hradec Králové, Charles University, Prague, Czech Republic.
Haithem ChtiouiLaboratory & Service of Medical Pharmacology, Department of Laboratory Medicine and Pathology, and Department of Medicine, University Hospital of Lausanne and University of Lausanne, Lausanne, Switzerland.
Laura E RothuizenLaboratory & Service of Medical Pharmacology, Department of Laboratory Medicine and Pathology, and Department of Medicine, University Hospital of Lausanne and University of Lausanne, Lausanne, Switzerland.
Aimable NahimanaService and Central Laboratory of Hematology, University Hospital of Lausanne and University of Lausanne, Lausanne, Switzerland.ORCID http://orcid.org/0000-0003-4968-3167
Axel BellottiService and Central Laboratory of Hematology, University Hospital of Lausanne and University of Lausanne, Lausanne, Switzerland.
Laurent R ChiarelliDepartment of Biology and Biotechnology, University of Pavia, Pavia, Italy.ORCID http://orcid.org/0000-0003-0348-9764
Dany SpaggiariLaboratory & Service of Medical Pharmacology, Department of Laboratory Medicine and Pathology, and Department of Medicine, University Hospital of Lausanne and University of Lausanne, Lausanne, Switzerland.
Neeraj DharGlobal Health Institute, School of Life Sciences, EPFL, Lausanne, Switzerland.ORCID http://orcid.org/0000-0002-5887-8137
Richa MishraGlobal Health Institute, School of Life Sciences, EPFL, Lausanne, Switzerland.
Raphaël SommerGlobal Health Institute, School of Life Sciences, EPFL, Lausanne, Switzerland.
Andréanne LupienGlobal Health Institute, School of Life Sciences, EPFL, Lausanne, Switzerland.
Michel A DuchosalService and Central Laboratory of Hematology, University Hospital of Lausanne and University of Lausanne, Lausanne, Switzerland.
Benoît GueryService of Infectious Diseases, University Hospital of Lausanne and University of Lausanne, Lausanne, Switzerland.
François R GirardinLaboratory & Service of Medical Pharmacology, Department of Laboratory Medicine and Pathology, and Department of Medicine, University Hospital of Lausanne and University of Lausanne, Lausanne, Switzerland.
Giuseppina MilanoService of Cardiac Surgery, University Hospital of Lausanne and University of Lausanne, Lausanne, Switzerland.
Olga RiabovaFederal Research Center "Fundamentals of Biotechnology RAS", Moscow, Russia.
Vadim MakarovInnovative Medicines for Tuberculosis (iM4TB), Lausanne, Switzerland.
Thierry BuclinLaboratory & Service of Medical Pharmacology, Department of Laboratory Medicine and Pathology, and Department of Medicine, University Hospital of Lausanne and University of Lausanne, Lausanne, Switzerland.ORCID http://orcid.org/0000-0003-0639-5536
Stewart T ColeInnovative Medicines for Tuberculosis (iM4TB), Lausanne, Switzerland.
Eva Choong *Laboratory & Service of Medical Pharmacology, Department of Laboratory Medicine and Pathology, and Department of Medicine, University Hospital of Lausanne and University of Lausanne, Lausanne, Switzerland.
Laurent A Decosterd *Laboratory & Service of Medical Pharmacology, Department of Laboratory Medicine and Pathology, and Department of Medicine, University Hospital of Lausanne and University of Lausanne, Lausanne, Switzerland. laurentarthur.decosterd@chuv.ch.ORCID http://orcid.org/0000-0002-9840-1325
Funding
Bill and Melinda Gates Foundation (GF) OPP1164837European Commission (EC) 853989Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (SNF) 324730-165956Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (SNF) 324730_192449Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (SNF) 326000-121314/1
Abstract
Macozinone (MCZ, PBTZ169) is a potent clinical-stage benzothiazinone antitubercular agent that covalently inhibits the essential mycobacterial flavoenzyme DprE1. In some mammals, MCZ undergoes reductive dearomatization to H
Identifiers
PMID
42844364What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.